10x Genomics Reviews Impressive Financial Progress for Q2 2026
In an exciting update for stakeholders and those following advancements in life science technology, 10x Genomics, Inc. (Nasdaq: TXG), headquartered in Pleasanton, California, has unveiled its financial results for the second quarter ending June 30, 2026. This quarterly report is noteworthy, not only for its figures but also for the significant strategic moves the company has made in recent months.
10x Genomics reported revenues amounting to $151.0 million for Q2 2026. When accounting for a $1.6 million patent litigation settlement, the effective revenue stands at $149.4 million. This shows a 3% increase compared to the same quarter in 2025, again excluding non-recurring settlement revenue from both years. The growth trajectory, though modest, is indicative of the company's resilience and operational efficiency. Gross margins rose to 74%, up from 72% in the same period last year, attributed to reduced manufacturing costs and inventory write-downs.
However, operating expenses soared to $132.1 million, up by 39% from the previous year, primarily due to a sharp decline in gains from legal settlements reported in the past. The increase in expenses primarily reflects strategic investments aimed at future growth. Unfortunately, this resulted in an operational loss of $19.6 million for the quarter, contrasting sharply with the operational income of $30.1 million reported in the year-ago period.
Net losses came to $17.9 million in Q2 2026, comparing unfavorably to net income of $34.5 million in the same quarter of 2025, underscoring the company's ongoing challenges as it navigates a competitive landscape.
Adding to the financial narrative, 10x Genomics completed the acquisition of Proteintech Genomics, enhancing its multiomics strategy. This acquisition signifies an important step in augmenting the company's capabilities in advanced protein detection, aligning with 10x’s goal of leading in single cell and spatial biology technologies. Furthermore, recent collaborations with notable institutions like the Cleveland Clinic and Lausanne University Hospital have been announced to foster research in innovative diagnostic applications leveraging these technologies, especially for cancer care.
CEO Serge Saxonov remarked on the extraordinary customer engagement with their new product, Atera, expressing optimism about the future. According to Saxonov, the early order flow is very encouraging, reflecting a positive response from the research community. This enthusiasm, combined with the company’s strong operational foundation, positions 10x Genomics to take advantage of emerging opportunities in life sciences and health technologies.
With these results in mind, 10x Genomics has updated its revenue guidance for the remainder of 2026. The new expectations suggest revenue between $610 million and $630 million, incrementally raised from the previous forecast. This 2% to 5% growth projection over the prior year affirms the company’s strategic planning amid a highly dynamic industry landscape.
In summary, while the financial highlights for Q2 2026 exhibit a mixed bag of growth and challenges, the strategic acquisitions and collaborations underscore a robust pipeline for future advancements. As 10x Genomics continues to evolve, its commitment to improving human health through innovative technology remains unwavering. Analysts and investors alike will be keenly watching how the company capitalizes on its recent investments and responds to the competitive pressures in the biotech sector. For more information, the company invites stakeholders to access the upcoming conference call slated for August 6, 2026, which will delve further into these results and future trajectories.
Financial Highlights
10x Genomics reported revenues amounting to $151.0 million for Q2 2026. When accounting for a $1.6 million patent litigation settlement, the effective revenue stands at $149.4 million. This shows a 3% increase compared to the same quarter in 2025, again excluding non-recurring settlement revenue from both years. The growth trajectory, though modest, is indicative of the company's resilience and operational efficiency. Gross margins rose to 74%, up from 72% in the same period last year, attributed to reduced manufacturing costs and inventory write-downs.
However, operating expenses soared to $132.1 million, up by 39% from the previous year, primarily due to a sharp decline in gains from legal settlements reported in the past. The increase in expenses primarily reflects strategic investments aimed at future growth. Unfortunately, this resulted in an operational loss of $19.6 million for the quarter, contrasting sharply with the operational income of $30.1 million reported in the year-ago period.
Net losses came to $17.9 million in Q2 2026, comparing unfavorably to net income of $34.5 million in the same quarter of 2025, underscoring the company's ongoing challenges as it navigates a competitive landscape.
Strategic Developments
Adding to the financial narrative, 10x Genomics completed the acquisition of Proteintech Genomics, enhancing its multiomics strategy. This acquisition signifies an important step in augmenting the company's capabilities in advanced protein detection, aligning with 10x’s goal of leading in single cell and spatial biology technologies. Furthermore, recent collaborations with notable institutions like the Cleveland Clinic and Lausanne University Hospital have been announced to foster research in innovative diagnostic applications leveraging these technologies, especially for cancer care.
Positive Outlook
CEO Serge Saxonov remarked on the extraordinary customer engagement with their new product, Atera, expressing optimism about the future. According to Saxonov, the early order flow is very encouraging, reflecting a positive response from the research community. This enthusiasm, combined with the company’s strong operational foundation, positions 10x Genomics to take advantage of emerging opportunities in life sciences and health technologies.
Future Guidance
With these results in mind, 10x Genomics has updated its revenue guidance for the remainder of 2026. The new expectations suggest revenue between $610 million and $630 million, incrementally raised from the previous forecast. This 2% to 5% growth projection over the prior year affirms the company’s strategic planning amid a highly dynamic industry landscape.
Conclusion
In summary, while the financial highlights for Q2 2026 exhibit a mixed bag of growth and challenges, the strategic acquisitions and collaborations underscore a robust pipeline for future advancements. As 10x Genomics continues to evolve, its commitment to improving human health through innovative technology remains unwavering. Analysts and investors alike will be keenly watching how the company capitalizes on its recent investments and responds to the competitive pressures in the biotech sector. For more information, the company invites stakeholders to access the upcoming conference call slated for August 6, 2026, which will delve further into these results and future trajectories.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.